Skip to main content

Market Overview

Wall Street's M&A Chatter From August 31: Barnes & Noble, Constellium, Daiichi Sankyo


The following are the M&A deals, rumors and chatter circulating on Wall Street for Thursday, August 31, 2017.

Barnes & Noble Denies Rumors Of Sale

The Rumor:

Barnes & Noble, Inc. (NYSE: BKS) has been working with Guggenheim on a potential sale, according to a report from DealReporter on Thursday. Sources said BKS has had discussions with private equity firms Apollo Global Management (NYSE: APO) and Platinum Equity.

A spokesperson for Barnes & Noble told Benzinga it was not in sale talks at this time.

Barnes & Noble closed at $7.75 on Thursday, up 45 cents.

Birla Said to Consider Bids for Constellium, Aleris

The Rumor:

Indian billionaire Kumar Mangalam Birla is considering bidding for Constellium NV (NASDAQ: CSTM) and Aleris Corp., according to sources as reported by Bloomberg. Talks are in a preliminary stage, the sources said.

Bloomberg reported in early August that Constellium was considering its options following receipt of takeover interest.

Constellium closed at $11.30, up 85 cents.

Daiichi Sankyo Denies Acquisition Offer from AstraZeneca

The Rumor:

AstraZeneca (NYSE: AZN) offered to buy Japan's Daiichi Sankyo Co (OTC: DSNKY) in 2016, according to sources as reported by Nikkei Business. The Japanese drugmaker declined the offer, the sources said.

Daiichi Sankyo responded to the report, later on Thursday, saying it had received no takeover offer from AstraZeneca. The UK drugmaker did not comment on the rumor.

AstraZeneca closed at $29.83, up 58 cents.


Related Articles (APO + AZN)

View Comments and Join the Discussion!

Posted-In: M&A News Rumors

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at